Abstract

BackgroundAntinuclear antibodies (ANA) determined by the HEp-2 cell assay are the primary screening test for connective tissue diseases (CTDs), i.e. systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögrens's...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Nailfold capillaroscopy and autoimmune connective tissue diseases in patients from a Portuguese nailfold capillaroscopy clinic.
Ana Lladó ... António Panarra
Rheumatology international | VOL. 40
Ana Lladó, et. al.Ana Lladó ... António Panarra
26 Aug 2019
Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia
Ulrich Costabel ... Josune Guzman
Respiration | VOL. 98
Ulrich Costabel, et. al.Ulrich Costabel ... Josune Guzman
29 Mar 2019
AB1018 Detection of ANTI-DFS70 antibodies by indirect immunofluorescence (IIF) on novel HEP-2/DFS70-KO substrate for discriminating antinuclear antibodies (ANA) – positive healthy individuals (HI) and patients with systemic lupus erythematosus (SLE)
A Novikov ... Z Verizhnikova
Annals of the Rheumatic Diseases | VOL. 76
A Novikov, et. al.A Novikov ... Z Verizhnikova
01 Jun 2017
Pediatric Systemic Lupus Erythematosus: More Than a Positive Antinuclear Antibody
J E Weiss
Pediatrics in Review | VOL. 33
J E WeissJ E Weiss
01 Feb 2012
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers